Cryo Cell International (CCEL) EBIT Margin (2010 - 2026)

Cryo Cell International has disclosed EBIT Margin across 17 years of filings, most recently posting 9.96% for Q1 2026.

• In Q1 2026, EBIT Margin fell 329.0% year-over-year to 9.96%; the TTM figure through Feb 2026 stood at 0.61% (down 195.0% YoY), while the FY2025 annual figure was 1.53%, down 31.0% from the prior year.
• EBIT Margin improved to 9.96% in Q1 2026, from 50.58% in the prior quarter.
• Over the last five years, EBIT Margin for CCEL reached as high as 24.29% in Q3 2025 and fell as low as 205.37% in Q4 2023.
• The 5-year median for EBIT Margin is 13.25% (2025), against an average of 7.18%.
• Annual changes were most pronounced in 2023 — EBIT Margin slumped 16773 bps — and 2024, when it jumped 16781 bps.
• A 5-year view of EBIT Margin shows it stood at 37.64% in 2022, then tumbled by 446 bps to 205.37% in 2023, then surged by 82 bps to 37.56% in 2024, then plunged by 35 bps to 50.58% in 2025, then jumped by 120 bps to 9.96% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 9.96%, 50.58%, and 24.29% for Q1 2026, Q4 2025, and Q3 2025 respectively.